We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

LINX Reflux Management System Clinical Study Protocol

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00776997
First Posted: October 22, 2008
Last Update Posted: December 18, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Torax Medical Incorporated
Results First Submitted: April 25, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Gastroesophageal Reflux
Intervention: Device: Magnetic Sphincter Augmentation

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
LINX System All subjects are treated with the LINX System during a laparoscopic surgical procedure. Subjects serve as their own control. Baseline measurements are compared to post-implant measurements.

Participant Flow:   Overall Study
    LINX System
STARTED   100 
COMPLETED   98 [1] 
NOT COMPLETED   2 
Adverse Event                2 
[1] 98 subjects evaluated at 12-months. Endpoint analysis based on all subjects treated (n=100)



  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Rate of Occurrence for Device and Procedure Related Serious Adverse Events (SAEs).   [ Time Frame: through 24 months ]

2.  Primary:   Normalization of Esophageal Acid Exposure Time or Reduced Total Acid Exposure Time of at Least 50% Compared to the Subject's Baseline Measurement by Esophageal pH Testing.   [ Time Frame: 12 Months ]

3.  Secondary:   At Least a 50% Reduction in Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL) Total Score Compared to Baseline   [ Time Frame: 12 months ]

4.  Secondary:   Average Daily Proton-pump Inhibitor (PPI) Dosage Reduced by at Least 50% Compared to Baseline   [ Time Frame: 12 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information